Molecular Pathways in Cancers 

<br/><br/><br/>English[eng] 
<br/><br/><label>ISBN: </label>9783040000000 
<br/><br/><label>Subjects--Topical Terms: </label><br/>actin cytoskeletal reorganization||breast cancer||CD99 agonist||EGFR dimerization||endocytosis||FAK dephosphorylation||PTPN12||Rac1||RhoA||tripeptide||OMD||PRELP||tumor suppression gene||bladder cancer initiation||tight junction||partial EMT||tousled-like kinase (TLK)||NIMA-related kinase 1 (NEK1)||yes-associated protein 1 (YAP1)||thioridazine (THD)||MS-determined phosphopeptides||human immunodeficiency virus type 1||epithelial cells||carcinogenicity||oxidative stress||reactive oxygen species||gp120||Tat||Nef||matrix protein p17||reverse transcriptase||mitochondria||metastasis||OXPHOS||cancer||Warburg effect||cancer therapeutics||myeloproliferative neoplasms||signaling pathways||JAK2||CALR||MPL||TPOR||DUSP1||MAPK||Snail||prostate cancer||migration and invasion||patient survival||biomarkers||pBRD4||SET||PP2A||prognosis||triple negative breast cancer||resistance||anti-receptor therapy||trastuzumab||PI3K||mTOR||TAK-228||epigenetic||methylation||acetylation||non-coding RNA||small-cell lung cancer||triple-negative breast cancer||pancreatic ductal adenocarcinoma||glioblastoma||metastatic melanoma||advanced ovarian cancer||hepatocellular carcinoma||immune evasion||immunotherapy||immune checkpoint inhibitors||oncogenic signaling pathway||molecular targeted agents||genome||epigenome||tumor immune microenvironment||ovarian cancer||adaptive immunity||innate immunity||complement system||cancer immunology||tumor microenvironment||splicing pathway||luminal breast cancer||BET inhibitors||n/a